Search

Displaying results 4191 - 4200 of 4334 in total
  1. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CA...

  2. Drug

    Verpasep caltespen

    go.drugbank.com/drugs/DB04959
    Investigational

    Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elici...

  3. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential t...

  4. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  5. Drug

    APD668

    go.drugbank.com/drugs/DB05166
    Experimental

    APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also av...

  6. Drug

    ABT-510

    go.drugbank.com/drugs/DB05434
    Investigational

    ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.

  7. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission. The vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine.

  8. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC).

  9. Drug

    Amitraz

    go.drugbank.com/drugs/DB11373
    ExperimentalVet approved

    Amitraz presents insect repellent effects and hence, it can be used as an insecticide and pesticide.

  10. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over